09989.HK
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 4.23
−0.59%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.2B | 5.5B | 5.3B | 5.4B | 7.2B |
| Cost of Revenue | 3.5B | 3.7B | 3.5B | 3.6B | 4.8B |
| Gross Profit | 1.7B | 1.7B | 1.8B | 1.8B | 2.3B |
| Operating Expenses | |||||
| R&D Expense | 205.7M | 226.2M | 212.0M | 184.7M | 252.1M |
| SG&A Expense | 537.2M | 478.2M | 454.7M | 590.1M | 665.0M |
| General & Admin Expense | 266.7M | 147.4M | 145.3M | 144.6M | 146.5M |
| Selling & Marketing Expense | 453.4M | 330.8M | 309.4M | 445.5M | 518.5M |
| Other Expenses | 812.4M | 402.7M | 348.1M | 1.9B | 294.7M |
| Total Operating Expenses | 1.6B | 1.1B | 1.0B | 2.7B | 1.2B |
| Cost and Expenses | 5.0B | 4.8B | 4.5B | 6.3B | 6.0B |
| Operating Income (EBIT) | 191.6M | 636.0M | 741.3M | (238.1M) | 1.1B |
| Non-Operating | |||||
| Interest Income | 39.2M | 38.3M | 44.4M | 39.5M | 54.1M |
| Interest Expense | 57.1M | 71.4M | 141.2M | 223.2M | 235.2M |
| Net Interest Income | (17.9M) | (33.2M) | (109.1M) | (199.2M) | (203.1M) |
| Other Non-Op Income/Expense | 7.5M | (233.7M) | (15.1M) | (690.2M) | (168.7M) |
| Non-Operating Income (excl Interest) | (13.7M) | 162.3M | (126.1M) | 467.0M | (66.5M) |
| EBT (Pre-Tax Income) | 199.1M | 402.2M | 726.2M | (928.3M) | 829.9M |
| Income Tax Expense | 32.1M | 59.6M | 101.3M | (126.2M) | 115.2M |
| Bottom Line | |||||
| Net Income | 202.9M | 349.5M | 646.7M | (783.3M) | 727.4M |
| Earnings from Cont. Ops | 196.3M | 342.6M | 624.9M | (802.2M) | 715.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 202.9M | 349.5M | 646.7M | (783.3M) | 727.4M |
| Per Share | |||||
| Basic EPS | HK$0.14 | HK$0.24 | HK$0.44 | (HK$0.53) | HK$0.50 |
| Diluted EPS | HK$0.14 | HK$0.24 | HK$0.44 | (HK$0.53) | HK$0.50 |
| Revenue Per Share | HK$3.57 | HK$3.73 | HK$3.60 | HK$3.71 | HK$4.88 |
| Shares | |||||
| Basic Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Diluted Shares Outstanding | 1.5B | 1.5B | 1.5B | 1.5B | 1.5B |
| Profitability Metrics | |||||
| EBITDA | 351.8M | 846.6M | 1.2B | (331.5M) | 1.4B |
| D&A | 310.9M | 372.9M | 331.1M | 373.6M | 307.7M |
| EBIT | 256.4M | 473.7M | 867.4M | (705.1M) | 1.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026